Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Peritoneal Metastases In Patients With Neuroendocrine Neoplasms: A Challenging Site Of Metastases With Clinical And Prognostic Implications

Peritoneal metastases in patients with neuroendocrine neoplasms: a challenging site of metastases with clinical and prognostic implications

M Tsoli1, H Wilson2, P Armonis2

  • 1Neuroendocrine Tumour Unit, ENETS Centre of Excellence, 1st Department of Propaedeutic and Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, Agiou Thoma 17, 11527, Athens, Greece. martso.mt@gmail.com.

Journal of Endocrinological Investigation
|March 7, 2024

Related Experiment Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.1K
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

10.9K
Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
07:43

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

26.6K

View abstract on PubMed

Summary
This summary is machine-generated.

Peritoneal metastases (PM) in neuroendocrine neoplasms (NENs) are uncommon but significantly impact patient survival. Early identification and treatment of PM are crucial for improving outcomes in NEN patients.

Area of Science:

  • Oncology
  • Gastroenterology
  • Surgical Oncology

Background:

  • Peritoneal metastases (PM) from neuroendocrine neoplasms (NENs) significantly affect patient quality of life and clinical status.
  • Increasing frequency of PM diagnosis necessitates understanding their characteristics and prognostic implications.

Purpose of the Study:

  • To identify the key characteristics of peritoneal metastases (PM) in neuroendocrine neoplasm (NEN) patients.
  • To evaluate the prognostic significance of PM in the overall survival (OS) of NEN patients.

Main Methods:

  • Retrospective analysis of NEN patients with PM from two tertiary referral centers.
  • Inclusion of a control group of age- and gender-matched stage IV NEN patients without PM.

Main Results:

Keywords:
Neuroendocrine neoplasmsPeritoneal metastasesPrognosis

Related Experiment Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.1K
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

10.9K
Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
07:43

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

26.6K
  • PM were identified in 10.3% of NEN patients, most commonly originating from the small intestine.
  • Patients with PM had a median overall survival (OS) of 142 months, compared to not reached in the control group.
  • Treatments included somatostatin analogues (76%) and peptide receptor radionuclide therapy (PRRT) (8.6%), with a median PFS of 15 months in the PRRT group.

Conclusions:

  • Peritoneal metastases (PM) are infrequent in NEN patients, primarily associated with small intestinal NENs and advanced disease.
  • The presence of PM negatively impacts the overall survival (OS) of NEN patients.
  • Prompt identification and management of PM are critical for improving patient prognosis.